Literature DB >> 8603847

Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas.

J W Streilein1, D Bradley, Y Sano, Y Sonoda.   

Abstract

PURPOSE: To use explants of cornea and iris and ciliary body (I/CB) of experimentally manipulated eyes to determine whether loss of the capacity to suppress T-cell activation in vitro correlates with other consequences of manipulation, i.e., the migration of Langerhans cells into the central corneal epithelium, the leakiness of stromal neovessels, and the presence of axons in the cornea.
METHODS: Mouse eyes were subjected to cautery of central corneal surface, suture-induced neovascularization, circumferential or criss-crossed corneal surface wounds, and orthotopic corneal grafting. Corneas and I/CB were excised, explanted in vitro, and assayed for capacity to suppress mixed lymphocyte reaction. Integrity of suture-induced corneal neovessels was assessed with high molecular weight dextran, Langerhans cells were enumerated in corneal epithelium, nerve axons were evaluated in corneal stroma, and capacity of manipulated eyes to support anterior chamber-associated immune deviation (ACAID) induction after anterior chamber injection of bovine serum albumin were assessed.
RESULTS: Experimental manipulations that abolished ACAID included cautery, neovascularization, and keratoplasty, whereas criss-crossed corneal excision wounds did not. Loss of ACAID correlated variably with loss of ability of corneal explants to secrete immunosuppressive factors in vitro, presence of Langerhans cells within the central corneal epithelium, leakiness of corneal neovessels, loss of axons in corneal stroma, and loss of ability of I/CB after keratoplasty to secrete immunosuppressive factors.
CONCLUSIONS: The cornea plays an active role in ocular immune privilege and ACAID by creating a local immunosuppressive microenvironment, providing neural afferent stimuli that affect immunosuppressive properties of I/CB, and preventing neovascularization and infiltration with Langerhans cells.

Entities:  

Mesh:

Year:  1996        PMID: 8603847

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  28 in total

Review 1.  Immunologic privilege of the eye.

Authors:  J W Streilein
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction.

Authors:  M Ueta; M-N Kweon; Y Sano; C Sotozono; J Yamada; N Koizumi; H Kiyono; S Kinoshita
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

3.  A novel inflammatory eye disease induced by lymphocytes from knockout mice sensitized against the deleted ocular antigen.

Authors:  M P Gelderman; P Charukamnoetkanok; J P Brady; L Hung; J S Zigler; E F Wawrousek; B P Vistica; E Fortin; C-C Chan; I Gery
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

4.  Expression of VEGF-C in rat cornea after alkali injury.

Authors:  Dongling Jiang; Yanhua Hu; Shiqi Ling
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

5.  Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Authors:  Claus Cursiefen; Lu Chen; Magali Saint-Geniez; Pedram Hamrah; Yiping Jin; Saadia Rashid; Bronislaw Pytowski; Kris Persaud; Yan Wu; J Wayne Streilein; Reza Dana
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

6.  Surgical denervation of ocular sympathetic afferents decreases local transforming growth factor-beta and abolishes immune privilege.

Authors:  Jose L Vega; Hiroshi Keino; Sharmila Masli
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

7.  Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1.

Authors:  Francesca Seta; Kiran Patil; Lars Bellner; Alexandre Mezentsev; Rowena Kemp; Michael W Dunn; Michal Laniado Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-05-21       Impact factor: 3.072

8.  Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation.

Authors:  Tina Dietrich; Felix Bock; Don Yuen; Deniz Hos; Björn O Bachmann; Grit Zahn; Stanley Wiegand; Lu Chen; Claus Cursiefen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

9.  Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival.

Authors:  Parisa Emami-Naeini; Thomas H Dohlman; Masahiro Omoto; Takaaki Hattori; Yihe Chen; Hyun Soo Lee; Sunil K Chauhan; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-05       Impact factor: 3.117

10.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.